Plopii

Plopii is a Brooklyn-based biotechnology and wellness company specializing in the development of paraxanthine-based formulations for cognitive enhancement, headache relief, and menstrual pain. Founded in 2026, the company leverages paraxanthine—caffeine's primary active metabolite—to deliver the cognitive and vasoconstrictive benefits of caffeine without its associated side effects, such as jitters, anxiety, and sleep disruption. Plopii's product portfolio includes commercially available nootropic oral pouches and energy drinks, alongside a pipeline of over-the-counter (OTC) pharmaceutical candidates. Key pipeline programs include a paraxanthine-based migraine and headache relief pill (combining paraxanthine, acetaminophen, and aspirin) and a vasoconstriction-free menstrual pain relief pill (Plopii Flow, combining paraxanthine, acetaminophen, and pyrilamine maleate) being developed under the FDA 505(b)(2) pathway.